iCAD, Inc. (ICAD)
|Net Income (ttm)||-14.71M|
|Day's Range||1.27 - 1.32|
|52-Week Range||1.16 - 4.68|
|Price Target||5.30 (+314.06%)|
|Earnings Date||Mar 28, 2023|
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calci... [Read more]
In 2021, iCAD, Inc.'s revenue was $33.64 million, an increase of 13.27% compared to the previous year's $29.70 million. Losses were -$11.25 million, -36.14% less than in 2020.Financial Statements
According to 12 analysts, the average rating for ICAD stock is "Buy." The 12-month stock price forecast is $5.3, which is an increase of 314.06% from the latest price.
7 Tantalizing Technology Stocks to Buy for Long-Term Growth
For the last two years, tech stocks have been weighed down by the Steet's worries about elevated inflation and the Fed's rate hikes in response to high inflation. But in the coming months, inflation i...
iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023
Company is exploring strategic options for its Therapy business line Company is exploring strategic options for its Therapy business line
New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists' Efficiency and Accuracy
Company's Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023 Company's Breast AI Suite of deep-learning breast cancer detectio...
iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI
Daniel Shea appointed as interim Chief Financial Officer
7 Drug Stocks That Will Soar in 2023
Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves...
Our 7 Top Nasdaq Stock Picks for 2023
On Dec. 5, U.S. stocks were dragged down in part by renewed bearishness on the part of Morgan Stanley (NYSE: MS) analyst Mike Wilson. However, with the U.S. services sector, the job market, and consu...
iCAD features Solis Mammography in upcoming “ProFound Insights, ProFound Impact” webinar
Solis Mammography's Chief Medical Officer Chirag Parghi, MD, to share clinical experience and real-world case studies demonstrating clinical value of ProFound AI Solis Mammography's Chief Medical Offi...
Positive New Research Presented at RSNA 2022 Reaffirms iCAD's Breast AI Suite Improves Radiologists' Performance and Breast Cancer Detection
Study affirms utility of ProFound AI's Case Scores in improving cancer detection
iCAD to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
NASHUA, N.H., Nov. 15, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey S...
Icad (ICAD) Reports Q3 Loss, Lags Revenue Estimates
Icad (ICAD) delivered earnings and revenue surprises of -7.14% and 26.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
iCAD Reports Financial Results for Third Quarter Ended September 30, 2022
Company implements corporate strategic realignment
iCAD to Join Forces with Radiology Partners, the Nation's Largest Radiology Practice
Strategic commercial agreement in development will leverage Radiology Partners' clinical expertise, ability to scale and leadership position to drive nationwide adoption of iCAD's Breast AI Suite Stra...
iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022
NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will ...
7 Little-Known Stocks With Millionaire-Maker Potential
Although, on the surface, everything looks gloomy now for stocks, one point that the bears are forgetting, I would argue, is that we live in an era of unprecedented technological advancement. Never be...
iCAD Customers in the U.S. and Europe Increasingly Adopting Company's Full Suite of Breast AI Technologies via Subscription Model
Flexible subscription model accelerates deployment of iCAD's Breast AI Suite, the only complete solution designed to comprehensively address today's top imaging challenges Flexible subscription model ...
After Plunging 29.6% in 4 Weeks, Here's Why the Trend Might Reverse for Icad (ICAD)
Icad (ICAD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates coul...
Icad (ICAD) Reports Q2 Loss, Lags Revenue Estimates
Icad (ICAD) delivered earnings and revenue surprises of 0% and 15.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
iCAD Reports Financial Results For Second Quarter 2022
Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will ...
iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology
Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general population Compelling clinical evidence...
ProFound AI Risk Real-World Case Studies to be featured in iCAD's “ProFound Insights, ProFound Impact” Webinar Series
Leading radiologists to highlight clinical examples demonstrating power of iCAD's complete suite of ProFound AI Breast Health Solutions Leading radiologists to highlight clinical examples demonstratin...
iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022
NASHUA, N.H., June 06, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company w...
5 Growth Stocks to Buy Now
EPS estimates are generally a strong indication of future growth. That's just one part of finding reliable growth stocks.
iCAD Announces CFO Transition
Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately